trending Market Intelligence /marketintelligence/en/news-insights/trending/jMFnyJWE-52Wx_THt8qfnw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA panel backs Merck & Co.'s Keytruda to treat type of bladder cancer

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US FDA panel backs Merck & Co.'s Keytruda to treat type of bladder cancer

A panel of outside advisers to the U.S. Food and Drug Administration voted 9 to 4 in favor of approving Merck & Co. Inc.'s blockbuster drug, Keytruda, for the treatment of high-risk, non-muscle invasive bladder cancer.

Keytruda, or pembrolizumab, is a checkpoint inhibitor — a tumor-targeting drug that blocks the PD-1 arm on healthy cells from linking up with a partner arm on the surface of cancer cells to spread the disease. The drug is already approved in the U.S. in multiple cancer indications.

SNL Image

During a Dec. 17 meeting, the majority of the Oncologic Drugs Advisory Committee voted that Keytruda, which is under a priority review by the FDA for treatment of high-risk, non-muscle invasive bladder cancer that has carcinoma in-situ, has the potential to treat the disease in patients who have limited nonsurgical treatment options.

Initial results from a phase 2 study, dubbed Keynote-057, showed that 38.8% of bladder cancer patients who received Keytruda in a mid-stage trial had no detectable cancer at three months.

According to Merck & Co.'s Dec. 17 press release, more than 80,000 new cases of bladder cancer will be diagnosed in 2019 in the U.S. and about 75% of bladder cancer patients have non-muscle invasive bladder cancer.

The FDA is set to decide on Keytruda's additional approval in January 2020. The U.S. regulator is not required to take the advisory committee's recommendation.